Onsite industrial wastewater treatment provider Axine Water Technologies has signed a multiyear service agreement with a pharmaceutical manufacturer to treat wastewater at its manufacturing plant located in the U.S. Midwest.

The wastewater, which is contaminated with active pharmaceutical ingredients (APIs) and solvents, is currently trucked off-site and incinerated.

Under the agreement, Axine will design, build, own, operate, and maintain an onsite wastewater treatment system at the customer’s facility. The system, based on Axine’s proprietary electrochemical oxidation technology, will destroy the APIs so the treated water can be safely discharged to sewer.

The agreement follows successful treatability testing to verify the cost and performance of Axine’s technology to treat the customer’s wastewater to meet local municipal wastewater permit requirements.

According to Axine, its solution will enable the pharmaceutical plant to generate immediate savings and improve operational efficiency. It is also expected to eliminate over 100,000 miles of trucking, eliminate more than eight million pounds of waste incineration, and reduce greenhouse gas emissions over the term of the agreement.

“Pharmaceutical companies worldwide have committed to reducing the environmental impact of their manufacturing operations,” said Jonathan Rhone, president and chief executive officer of Axine. “This project is a great example of how Axine is establishing a new standard of care for treating APIs in pharmaceutical manufacturing waste streams to help the pharmaceutical industry achieve its sustainability goals while reducing the cost, risk, and impact of pharmaceuticals in the environment.

Development and commercialization of Axine’s technology is supported by the National Research Council of Canada – Industrial Research Assistance Program (NRC – IRAP) and Sustainable Development Technology Canada (SDTC).

See also  Alberta Start-Up Provides In Situ Testing for E. coli

“Axine’s innovative wastewater treatment technology is addressing a global problem in the pharmaceutical industry that will ensure safe treatment of wastewater amongst a wide range of sustainability, productivity, and health benefits,” said Leah Lawrence, president and chief executive officer of SDTC. “We’re very pleased to support Axine’s scale-up efforts to compete in international markets using cutting edge technologies to advance sustainability efforts around the world.”

LEAVE A REPLY

Please enter your name here
Please enter your comment!